- Home
- IONS vs FSS Comparison
IONS vs FSS Comparison
Compare IONS & FSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- FSS
- Stock Information
- Founded
- IONS 1989
- FSS 1901
- Country
- IONS United States
- FSS United States
- Employees
- IONS N/A
- FSS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- FSS Auto Manufacturing
- Sector
- IONS Health Care
- FSS Consumer Discretionary
- Exchange
- IONS Nasdaq
- FSS Nasdaq
- Market Cap
- IONS 6.0B
- FSS 5.2B
- IPO Year
- IONS 1991
- FSS N/A
- Fundamental
- Price
- IONS $36.91
- FSS $96.97
- Analyst Decision
- IONS Buy
- FSS Buy
- Analyst Count
- IONS 18
- FSS 2
- Target Price
- IONS $62.00
- FSS $90.00
- AVG Volume (30 Days)
- IONS 1.5M
- FSS 320.3K
- Earning Date
- IONS 11-06-2024
- FSS 10-31-2024
- Dividend Yield
- IONS N/A
- FSS 0.50%
- EPS Growth
- IONS N/A
- FSS 44.95
- EPS
- IONS N/A
- FSS 3.45
- Revenue
- IONS $803,067,000.00
- FSS $1,837,900,000.00
- Revenue This Year
- IONS N/A
- FSS $9.77
- Revenue Next Year
- IONS $19.61
- FSS $7.46
- P/E Ratio
- IONS N/A
- FSS $27.73
- Revenue Growth
- IONS 30.57
- FSS 10.33
- 52 Week Low
- IONS $33.33
- FSS $71.29
- 52 Week High
- IONS $54.44
- FSS $102.18
- Technical
- Relative Strength Index (RSI)
- IONS 52.98
- FSS 53.67
- Support Level
- IONS $36.39
- FSS $95.19
- Resistance Level
- IONS $38.90
- FSS $98.02
- Average True Range (ATR)
- IONS 1.33
- FSS 1.77
- MACD
- IONS 0.23
- FSS -0.49
- Stochastic Oscillator
- IONS 51.63
- FSS 21.06
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About FSS Federal Signal Corporation
Federal Signal Corp designs and manufactures products and integrated solutions for municipal, governmental, industrial, and airport customers. It operates in the segments of Environmental Solutions Group and the Safety and Security Systems Group. The Environmental Solutions group manufactures and supplies street sweeper vehicles, sewer cleaner and vacuum loader trucks, hydro-excavation trucks, high-performance water blasting equipment, dump truck bodies, and trailers. The Safety and Security Systems Group offers comprehensive systems and products such as campus and community alerting, emergency vehicles, first responder interoperable communications, and others. The company generates a majority of its revenue from the Environmental Solutions Group segment.